Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | CFB | P00751 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | IL33 | O95760 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929192 | 0.91 | KMT2A (0.39) | OPRK1OPRM1KDM4EALDH1A1MAPT | |
| SCHEMBL5929122 | 0.91 | KMT2A (0.41) | KDM4EALDH1A1MAPTRAB9ADRD2 | |
| SCHEMBL5929310 | 0.84 | KMT2A (0.38) | OPRK1OPRM1KDM4EALDH1A1MAPT | |
| SCHEMBL5928924 | 0.84 | KMT2A (0.37) | OPRK1OPRM1CFBKDM4EALDH1A1 | |
| SCHEMBL5929300 | 0.83 | KDM4E (0.41) | OPRK1OPRM1KDM4EALDH1A1MAPT | |
| SCHEMBL5929198 | 0.83 | KDM4E (0.45) | KDM4EALDH1A1MAPTRAB9ADRD2 | |
| SCHEMBL5929363 | 0.83 | KMT2A (0.39) | OPRK1OPRM1CFBKDM4EALDH1A1 | |
| SCHEMBL5929296 | 0.83 | GAA (0.35) | OPRK1OPRM1CFBKDM4EALDH1A1 | |
| SCHEMBL5929141 | 0.83 | KMT2A (0.38) | CFBKDM4EALDH1A1MAPTRAB9A | |
| SCHEMBL5929073 | 0.82 | KMT2A (0.40) | OPRK1OPRM1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | NEUROGEN CORPORATION (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | C5AR1, C5AR2, C3AR1 | OPRK1 523/4885OPRM1 580/4885CFB 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.